El-Kamel Amal H, Al-Shora Doaea H, El-Sayed Yousry M
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
J Microencapsul. 2006 Jun;23(4):389-404. doi: 10.1080/02652040500444230.
Cellulose propionate (CP) microparticles containing captopril (CAP) were prepared by solvent evaporation technique. The effects of polymer molecular weight, polymer composition and drug:polymer ratios on the particle size, flow properties, morphology, surface properties and release characteristics of the prepared captopril microparticles were examined. The anti-hypertensive effect of the selected CAP formulation in comparison with aqueous drug solution was also evaluated in vivo using hypertensive rats. The formulation containing drug:polymer blend ratio 1:1.5 (1:1 low:high molecular weight CP), namely F7, was chosen as the selected formulation with regard to the encapsulation efficiency (75.1%), flow properties (theta=24 degrees, Carr index=5%, Hausner ratio=1.1, packing rate=0.535) and release characteristics. Initial burst effect was observed in the release profile of all examined formulations. DSC and SEM results indicated that the initial burst effect could be attributed to dissolution of CAP crystals present on the surface or embedded in the superficial layer of the matrix. The release kinetics of CAP from most microparticle formulations followed diffusion mechanism. After oral administration of the selected microparticle formulation (F7) to hypertensive rats, systolic blood pressure decreased gradually over 24 h compared to reference drug solution. These results may suggest the potential application of cellulose propionate microparticles as a suitable sustained release drug delivery system for captopril.
采用溶剂蒸发技术制备了含卡托普利(CAP)的丙酸纤维素(CP)微粒。考察了聚合物分子量、聚合物组成以及药物与聚合物比例对所制备的卡托普利微粒的粒径、流动性质、形态、表面性质和释放特性的影响。还使用高血压大鼠在体内评估了所选卡托普利制剂与药物水溶液相比的抗高血压效果。就包封率(75.1%)、流动性质(休止角=24°,卡尔指数=5%,豪斯纳比=1.1,填充率=0.535)和释放特性而言,选择药物与聚合物共混比例为1:1.5(1:1低分子量:高分子量CP)的制剂,即F7,作为所选制剂。在所有考察制剂的释放曲线中均观察到初始突释效应。差示扫描量热法(DSC)和扫描电子显微镜(SEM)结果表明,初始突释效应可归因于存在于基质表面或嵌入基质表层的卡托普利晶体的溶解。大多数微粒制剂中卡托普利的释放动力学遵循扩散机制。给高血压大鼠口服所选微粒制剂(F7)后,与参比药物溶液相比,收缩压在24小时内逐渐降低。这些结果可能表明丙酸纤维素微粒作为卡托普利合适的缓释药物递送系统具有潜在应用价值。